For years, MASH was where drug development dreams went to die. | After Rezdiffra’s approval and Wegovy’s label expansion, ...
On Friday, August 15, the FDA approved Wegovy (semaglutide) as the first-ever GLP-1 therapy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) — a pivotal moment in the fight ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback